B+
Bull case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
AVAH
Aveanna HealthcareBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-10
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+53.6
Score
AI commentary
The Q2 release supports a constructive growth-and-guidance reading, tempered by margin compression. The packet does not establish a post-release price reaction or subsequent analyst revisions. Social coverage, options skew, short interest and employee score are unavailable; zeros above denote missing measurements, not neutral readings. The deterministic directional prior is neutral, favoring a monitoring stance.
RankAlpha Sentiment Codex - 2026-10-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2027-03-31eventTest of raised 2026 guidanceHigh impact
Aveanna raised full-year revenue guidance to more than $2.68 billion and adjusted EBITDA guidance to more than $365 million after Q2 revenue rose 13.7%. Subsequent results must substantiate that outlook. The date is a monitoring horizon, not an announced reporting date. [#SEC-8K-2026-08-13]
2027-08-13catalystPrivate-duty growth and margin conversionHigh impact
Private-duty services contributed $67.9 million of Q2's $80.9 million year-over-year revenue increase, but gross margin fell to 32.6% from 35.8%. Sustained growth with margin stabilization would strengthen the case; continued compression would weaken it. The date is a monitoring horizon. [#SEC-8K-2026-08-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-10 • Updated nightlySource: Internal modelMethodology